David Lebovitz
Stock Analyst at Citigroup
(2.42)
# 1,342
Out of 4,424 analysts
40
Total ratings
50.91%
Success rate
-3.42%
Average return
Main Sectors:
Top Industries:
14 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $24.76 | +53.47% | 1 | May 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $389 → $382 | $205.25 | +86.11% | 2 | May 8, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $94 → $91 | $81.03 | +12.30% | 1 | Apr 25, 2024 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $68 | $48.00 | +41.67% | 1 | Mar 6, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $237 → $227 | $150.47 | +50.86% | 16 | Feb 16, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $32.25 | -47.29% | 5 | Oct 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $111 → $92 | $106.70 | -13.78% | 3 | Feb 1, 2022 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | n/a | $39.08 | - | 2 | Mar 23, 2021 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | n/a | $39.14 | - | 2 | Mar 2, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | n/a | $3.31 | - | 1 | Feb 26, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | n/a | $7.00 | - | 3 | Feb 22, 2021 | |
| KPTI Karyopharm Therapeutics | Initiates: Overweight | n/a | $1.09 | - | 1 | Jul 2, 2020 | |
| ASND Ascendis Pharma | Maintains: Overweight | n/a | $133.46 | - | 1 | Apr 2, 2020 | |
| AVRO AVROBIO | Maintains: Overweight | n/a | $1.23 | - | 1 | Mar 31, 2020 |
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $24.76
Upside: +53.47%
Madrigal Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $389 → $382
Current: $205.25
Upside: +86.11%
BioMarin Pharmaceutical
Apr 25, 2024
Maintains: Neutral
Price Target: $94 → $91
Current: $81.03
Upside: +12.30%
Crinetics Pharmaceuticals
Mar 6, 2024
Initiates: Buy
Price Target: $68
Current: $48.00
Upside: +41.67%
Alnylam Pharmaceuticals
Feb 16, 2024
Maintains: Buy
Price Target: $237 → $227
Current: $150.47
Upside: +50.86%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $32.25
Upside: -47.29%
Blueprint Medicines
Feb 1, 2022
Maintains: Equal-Weight
Price Target: $111 → $92
Current: $106.70
Upside: -13.78%
Ionis Pharmaceuticals
Mar 23, 2021
Maintains: Underweight
Price Target: n/a
Current: $39.08
Upside: -
Rhythm Pharmaceuticals
Mar 2, 2021
Maintains: Overweight
Price Target: n/a
Current: $39.14
Upside: -
MacroGenics
Feb 26, 2021
Maintains: Underweight
Price Target: n/a
Current: $3.31
Upside: -
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $7.00
Upside: -
Karyopharm Therapeutics
Jul 2, 2020
Initiates: Overweight
Price Target: n/a
Current: $1.09
Upside: -
Ascendis Pharma
Apr 2, 2020
Maintains: Overweight
Price Target: n/a
Current: $133.46
Upside: -
AVROBIO
Mar 31, 2020
Maintains: Overweight
Price Target: n/a
Current: $1.23
Upside: -